The best treatment for malaria depends on the type of malaria, how severe it is, and where you were infected, but for most uncomplicated Plasmodium falciparum infections the current standard is artemisinin‑based combination therapy (ACT), and a powerful new combination called ganaplacide–lumefantrine (GanLum/KLU156) is emerging as a major next‑generation option in trials.

⚠️ First: a serious safety note

Malaria can be rapidly fatal, especially falciparum malaria and in young children, pregnant women, and non‑immune travelers.

Self‑treating at home or delaying care is dangerous.

  • Anyone with possible malaria symptoms (fever, chills, headache, body pain) after being in a malaria area needs urgent in‑person medical care the same day.
  • The “best” treatment is always what a qualified clinician chooses after confirming the diagnosis, species, and severity.

What doctors use now (uncomplicated malaria)

For uncomplicated malaria (not affecting brain, lungs, or causing shock), the mainstay worldwide is artemisinin‑based combination therapy (ACT).

Common ACT regimens include:

  • Artemether–lumefantrine (e.g., Coartem)
  • Artesunate–amodiaquine
  • Dihydroartemisinin–piperaquine
  • Artesunate–mefloquine

Key points:

  • ACTs combine a fast‑acting artemisinin drug (kills most parasites quickly) with a longer‑acting partner drug (cleans up remaining parasites and reduces recurrence).
  • For most adults and children with uncomplicated falciparum malaria, 3 days of ACT is standard, with dosing adjusted for weight and local guidelines.
  • Choice of specific ACT varies by country , resistance patterns, pregnancy status, and age.

For non‑falciparum species (like P. vivax or P. ovale), many guidelines still use ACT or chloroquine depending on local resistance, plus primaquine or tafenoquine to clear liver forms and prevent relapse (after checking for G6PD deficiency).

Severe malaria: best treatment in hospital

For severe malaria (e.g., confusion/coma, seizures, severe anemia, breathing difficulty, shock, kidney injury), experts recommend intravenous artesunate as first‑line treatment.

  • IV artesunate is given for at least 24 hours, then followed by an oral ACT when the patient can swallow and parasites are lower.
  • Supportive care (fluids, oxygen, blood transfusions, managing complications) is often lifesaving and must be done in a hospital.

In some places where IV artesunate is not immediately available, other IV drugs (like quinine or quinidine) may be used temporarily, but the modern gold standard is IV artesunate.

What’s new and “best‑in‑class” right now?

The most exciting development is a new combination : ganaplacide–lumefantrine , also called GanLum or KLU156.

Why GanLum matters

Large Phase III trials in more than 1,600–1,600+ patients across 12 African countries showed:

  • Cure rates of about 97–99% , non‑inferior or slightly better than standard Coartem (artemether–lumefantrine).
  • Strong activity against parasites carrying K13 mutations linked to partial artemisinin resistance.
  • Once‑daily dosing for 3 days , which may improve adherence.

Experts describe GanLum as potentially the first major innovation in malaria treatment since 1999 , with a completely new mechanism of action for ganaplacide, targeting parasite protein transport inside red blood cells.

Important caveat:

  • As of late 2025, GanLum is still going through regulatory approval and may not yet be widely available in all countries.
  • Until it is fully approved and distributed, ACTs (especially artemether–lumefantrine) remain the routine first choice.

Quick HTML table – core treatments

Below is a simple HTML table summarizing the main treatment options by situation:

html

<table>
  <thead>
    <tr>
      <th>Clinical situation</th>
      <th>Preferred treatment</th>
      <th>Notes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Uncomplicated falciparum malaria (most adults/children)</td>
      <td>Artemisinin-based combination therapy (e.g., artemether–lumefantrine)</td>
      <td>3-day oral regimen; choice depends on region and guidelines.[web:4][web:10]</td>
    </tr>
    <tr>
      <td>Uncomplicated non-falciparum (e.g., P. vivax)</td>
      <td>ACT or chloroquine plus primaquine/tafenoquine</td>
      <td>Radical cure for liver stages; G6PD testing required before primaquine/tafenoquine.[web:4]</td>
    </tr>
    <tr>
      <td>Severe malaria (any species, esp. falciparum)</td>
      <td>Intravenous artesunate, then oral ACT</td>
      <td>Hospital care with intensive monitoring and supportive treatment.[web:4]</td>
    </tr>
    <tr>
      <td>Future and emerging first-line option</td>
      <td>Ganaplacide–lumefantrine (GanLum/KLU156)</td>
      <td>High cure rates (~97–99%); promising against resistant strains; pending/early approvals.[web:3][web:5][web:1]</td>
    </tr>
  </tbody>
</table>

How doctors decide “the best” for you

Clinicians don’t just pick the strongest drug; they balance benefit, safety, and resistance.

They consider:

  1. Species of Plasmodium
    • Falciparum vs non‑falciparum determines need for ACT vs chloroquine and liver‑stage treatment.
  1. Severity
    • Any sign of severe disease → IV artesunate in hospital.
  1. Where you were infected
    • Some regions have chloroquine resistance or emerging artemisinin resistance, which affects the recommended regimen.
  1. Age, pregnancy, and comorbidities
    • First trimester pregnancy has more restrictions on artemisinin use; specific regimens recommended in guidelines.
  1. Drug availability and local guidelines
    • National protocols (e.g., WHO, Canadian or US guidelines) set the practical “best treatment” locally.

Forum-style perspective: what people are discussing now

“In our clinic in West Africa, Coartem is still our workhorse, but we are watching GanLum very closely. Anything that beats resistance is a game changer.”

A few themes that come up in professional and public discussion:

  • Hope about resistance
    Growing concern about artemisinin‑resistant falciparum strains in Africa is driving excitement around new‑mechanism drugs like ganaplacide.
  • Access vs innovation
    Even if GanLum is approved, getting it to remote communities at scale, at an affordable price, is a big challenge being debated by global‑health experts.
  • Prevention is still king
    Insecticide‑treated nets, indoor spraying, and vaccines (like RTS,S and R21/Matrix‑M) are increasingly discussed alongside treatment because preventing infection avoids needing drugs at all.

If you or someone you know might have malaria

Here’s a practical step‑by‑step outline:

  1. Do not wait to “see if it passes.”
    Fever after being in a malaria area is an emergency until proven otherwise.

  2. Go to the nearest clinic/hospital immediately.
    Ask specifically for a malaria test (microscopy or rapid diagnostic test).

  1. Tell them where and when you traveled.
    This guides which species and resistance patterns are likely.

  1. Follow the exact treatment course given.
    Finish all doses, even if you feel better after one or two days.

  2. Return if symptoms persist or recur.
    Some people need repeat testing or a switch in regimen.

TL;DR

  • For most patients today, the best‑proven treatment is artemisinin‑based combination therapy (ACT) , with IV artesunate as the standard for severe malaria.
  • A new combination, ganaplacide–lumefantrine (GanLum/KLU156) , has shown excellent results and strong activity against resistant parasites and is likely to become a major option as approvals roll out.
  • The actual “best” treatment for any individual must be chosen by a clinician, based on species, severity, location of infection, and patient factors.

Information gathered from public forums or data available on the internet and portrayed here.